Based on a new generation of protein ubiquitination and its degradation and X-Synergy® new drug combination technology platform and other proprietary technologies, the development of new class I small molecule targeted immunomodulatory innovative drugs.
Learn, Kangpu Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Kangpu Biomedicine” has completed nearly RMB 100 million Pre-B round of financing, jointly led by China-China Venture Capital and Recapital Investment, and the old shareholder Aurora Ventures (A round of investors) continues to vote. Dr. Ge Chuansheng, founder, chairman and CEO of Kangpu Biomedicine, said: This round of financing will accelerate the pace of clinical trials of the company’s projects and accelerate the preclinical development of other innovative drug candidates.
Kangpu Biomedical was established in 2011 and is headquartered in Shanghai Zhangjiang Hi-Tech Park. It is an innovative bio-pharmaceutical company in the clinical stage, focusing on cancer, autoimmune diseases, inflammation and other therapeutic areas, mainly with a new generation of protein. Based on its proprietary technology, such as ubiquitination and its degradation and X-Synergy® new drug technology platform, it develops a new class I small molecule targeted immunomodulatory innovative drug.
Kangpu Biomedical Research and Development Pipeline
Understanding, Currently, the company is already treating prostate cancer, myelodysplastic syndrome, diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, inert cell lymphoma, systemic lupus erythematosus Multiple R&D pipelines (shown above) have been established in diseases such as psoriasis and arthritis, including several innovative drugs with the potential of First-in-Class or Best-in-Class, Two of the innovative drugs have entered the Phase I clinical trial phase in the United States.
In particular, its Independently developed Class I innovative drug KPG-121 combined with Enzalutamide for the treatment of metastatic castration-resistant prostate Phase I clinical trials of cancer (mCRPC) have been launched in the United States.This study was designed to evaluate the safety, tolerability, pharmacokinetic properties of KPG-121 and its initial anti-tumor effect with enzalutamide.
It is reported, KPG-121 is a new generation of lenalidomide derivative, belonging to CRBN E3 ubiquitin ligase ) CRL4CRBN regulator. Preclinical studies have shown that KPG-121 has greater immunomodulatory activity and more pronounced anti-angiogenic function than lenalidomide. A number of in vitro and in vivo biological studies have shown that KPG-121, when combined with an androgen receptor pathway modulator, produces a strong synergistic effect against prostate cancer.
Compared with ingeramide, Abiraterone Acetate, Apalutamide or Darolutamide alone, the combination with KPG-121 significantly increased the proliferation and antitumor effect of prostate cancer cells. . In addition, KPG-121 also has a highly effective inhibitory effect on multiple hematological tumors such as multiple myeloma and myelodysplastic syndrome.
About investment logic, Guozhong Ventures believes that Kangpu Biomedical uses a series of new small molecule immunomodulatory targeted drugs developed by the mechanism of protein ubiquitination and degradation to overcome existing drugs. The new thinking is provided by the drug resistance, the significant improvement of the effectiveness of the drug and the safety of long-term medication. At present, the development of new drugs based on the ubiquitin-proteasome system has also attracted many multinational pharmaceutical companies. like Roche, Pfizer, Merck, Novartis and GlaxoSmithKline have also invested. Billions of dollars to develop small molecule new drugs for protein degradation.
From the perspective of market demand, the investment in rehabilitation means that in the world, especially in China, the incidence of advanced prostate tumors, systemic lupus erythematosus and various hematological malignancies is increasing, and the huge clinical demand has not yet been satisfied.